License Pathogen Capture Technology.
Partners receive rights, technical evidence and formulation expertise — not just a specification sheet. PCT is a formulation step, not a reformulation programme: supplied in the form your process needs and added at an existing step, typically without new capital equipment.
Why partner with Aquila
- Defensible differentiation
- PCT is patent-protected and available only under a direct licence and supply agreement.
- Exclusivity by field and territory
- Rights are granted by field of use, format and territory, with performance commitments attached.
- Evidence for your claims
- Capture data, organism lists and studies, shared under NDA.
- The Aquila Innovation Lab
- Formulation trials and sample production runs.
- A proven route to market
- Formulation, quality systems, regulatory registration and commercial manufacture already completed.
- AMR and ESG alignment
- Non-biocidal, no known resistance mechanism, and a biodegradable carrier.
What could you build with PCT?
Final claims depend on market, regulatory route and feasibility data.
Skincare and acne care
Tested against named skin organisms, including Cutibacterium acnes, Candida albicans and Malassezia furfur.
Example concept from Aquila: a blemish-care gel or cleansing wipe that captures blemish-associated bacteria without the dryness associated with biocidal actives.
Typical formats
- Gels and serums
- Wipes
Intimate and feminine hygiene
Alcohol-free and biocide-free, suited to mucosa and repeat use.
Typical formats
- Wipes
- Rinses and washes
- Gels and serums
Surgical, wound and peri-operative
Wound dressings and device formats built around physical capture.
Typical formats
- Dressings
- Medical devices
Clinical and facility hygiene
Hygiene for skin and surfaces in clinical and dental settings.
Typical formats
- Wipes
- Sprays
Household hygiene
Pathogen removal for shared spaces with no biocidal actives.
Typical formats
- Wipes
- Sprays
Air and water filtration
Air, water and diagnostic filtration using the PCT capture mechanism.
Typical formats
- Filters
Coatings and paints
Licensed conversion with coatings, paints, textiles and filter media partners.
Typical formats
- Coatings and paints
Food, produce and agriculture
Listed by Aquila as an application route for PCT.
Typical formats
- Rinses and washes
- Coatings and paints
Defence and CBRN
First developed with the Irish Defence Forces to remove biothreats from skin.
Typical formats
- Wipes
Aviation and space
Exploratory. Aquila joined the ESA Discovery Programme in 2025–26.
Typical formats
- Wipes
- Filters
What a PCT partnership includes
- Licensed rights in your field, format and territory
- Quality-assured supply under an ISO 13485 certified system
- Formulation protocol and technical dossier
- Capture data and regulatory support
- You own your formulation, brand and customers
Licence fees, pricing, territory and volumes are discussed under NDA.
Who we partner with
- Brand owners
- Personal care, intimate hygiene, household, clinical and wound care, medical devices, oral and nasal care.
- Contract manufacturers and ODMs
- Under a global licensing agreement.
- Technology and format partners
- Coatings, paints, textiles and filter media — licensed conversion where Aquila retains the IP.
- Research and clinical collaborators
- Scoped Innovation Lab programmes and joint funding applications.
- Distributors and retailers
- Directed to licensed partners.
Proven in market
- AB Decontamination Device — FDA-registered and in market; the reference product for the wipe format.
- ISO 13485 certified quality system for medical device design and manufacture.
- Agency validation under European Defence Agency and Irish Defence Forces programmes.
Before you get in touch
How long does it take?
It depends more on your format and regulatory route than on PCT.
Is exclusivity available?
Yes — by field, format and territory, tied to performance commitments.
What does it cost?
Shared under NDA, with indicative terms provided before feasibility.
Who owns the IP?
You own your formulation and brand; the PCT platform and patents remain Aquila's.
Do you do joint ventures?
No. Partnerships use licence and supply agreements.
We only have an early idea.
Pre-commercialisation R&D through a scoped Innovation Lab study is available.
Send a partnership enquiry
- 1
A member of the commercial team replies personally.
- 2
If there is a fit, a mutual NDA and a fit conversation follow.
- 3
If there is not, the team explains why.
This form opens your email app with a pre-filled message to commercial@aquilabioscience.com. Nothing is sent until you send it.